Edition:
United States

Opexa Therapeutics Inc (OPXA.PH)

OPXA.PH on Philadelphia Stock Exchange

1.26USD
9 Dec 2016
Change (% chg)

$0.46 (+56.17%)
Prev Close
$0.81
Open
$1.15
Day's High
$1.43
Day's Low
$1.05
Volume
5,527
Avg. Vol
1,681
52-wk High
$4.82
52-wk Low
$0.56

Latest Key Developments (Source: Significant Developments)

Opexa Therapeutics reports Q2 loss per share $0.30
Thursday, 11 Aug 2016 04:01pm EDT 

Opexa Therapeutics Inc : Opexa Therapeutics reports second quarter 2016 financial results and provides corporate update . Q2 loss per share $0.30 .Q2 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S.  Full Article

Opexa Therapeutics Q1 loss per share $0.31
Thursday, 12 May 2016 04:01pm EDT 

Opexa Therapeutics Inc : Opexa therapeutics reports first quarter 2016 financial results and provides corporate update .Q1 loss per share $0.31.  Full Article

Opexa Therapeutics, Inc says granting of new t-cell patents covering tcelna
Tuesday, 6 Oct 2015 07:00am EDT 

Opexa Therapeutics, Inc:Says granting of new t-cell patents covering tcelna.  Full Article

Opexa Therapeutics Inc secures private funding
Tuesday, 1 Sep 2015 06:00am EDT 

Opexa Therapeutics Inc:Secures private funding for its nmo orphan development program, including planned phase i/ii clinical study.Says entered into a stock purchase agreement with a private investor to fund the company's nmo program.Stock purchase agreement with a private investor for up to $5 million, upon achievement of certain pre-specified milestones.  Full Article

Opexa Therapeutics Inc amends agreement with Merck Serono
Monday, 9 Mar 2015 07:00am EDT 

Opexa Therapeutics Inc:Says that it has amended its option and license agreement with Merck Serono (a division of Merck, Darmstadt, Germany) and will receive a $3 million payment.Says payment provides support for ongoing phase 2b clinical study of Tcelna((reg))( imilecleucel-T ), Opexa's personalized immunotherapy in development for patients with secondary progressive MS (SPMS), as well as preparation and planning of potential phase 3 studies.  Full Article

Opexa Therapeutics Inc files registration statement for rights offering
Wednesday, 28 Jan 2015 06:05am EST 

Opexa Therapeutics Inc:Says it has filed a registration statement with the Securities and Exchange Commission (SEC) for a proposed rights offering of subscription rights to purchase units comprised of a share of Opexa common stock and warrants to purchase an additional share of Opexa common stock.Says it would distribute one non-transferable subscription right for each share of common stock held on the record date.Says each right would entitle the holder to purchase one unit, composed of one share of common stock and a warrant to purchase one share of common stock, at a subscription price to be determined prior to the effective date of the registration statement.Says it also intends to distribute the non-transferable subscription rights to holders of its Series L warrants who are entitled to participate in the rights offering pursuant to the terms of the warrants held by them.Says it plans to use the proceeds from the rights offering primarily to complete funding the ongoing Phase IIb Abili T clinical study of Tcelna in patients with secondary progressive multiple sclerosis (SPMS) through completion and data release, expected in the H2 2016.  Full Article

BRIEF-Opexa Therapeutics receives notice from Ares Trading S.A. Unit of Merck Serono

* Opexa Therapeutics - On Nov 23, co received notice from Ares Trading S.A. Unit of Merck Serono